255 related articles for article (PubMed ID: 14749510)
21. In the lipodystrophy associated with highly active antiretroviral therapy, pseudo-Cushing's syndrome is associated with increased regeneration of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue.
Sutinen J; Kannisto K; Korsheninnikova E; Nyman T; Ehrenborg E; Andrew R; Wake DJ; Hamsten A; Walker BR; Yki-Järvinen H
Diabetologia; 2004 Oct; 47(10):1668-71. PubMed ID: 15455200
[TBL] [Abstract][Full Text] [Related]
22. Liver-selective transgene rescue of hypothalamic-pituitary-adrenal axis dysfunction in 11beta-hydroxysteroid dehydrogenase type 1-deficient mice.
Paterson JM; Holmes MC; Kenyon CJ; Carter R; Mullins JJ; Seckl JR
Endocrinology; 2007 Mar; 148(3):961-6. PubMed ID: 17170103
[TBL] [Abstract][Full Text] [Related]
23. 11β-Hydroxysteroid dehydrogenase type 1 shRNA ameliorates glucocorticoid-induced insulin resistance and lipolysis in mouse abdominal adipose tissue.
Wang Y; Yan C; Liu L; Wang W; Du H; Fan W; Lutfy K; Jiang M; Friedman TC; Liu Y
Am J Physiol Endocrinol Metab; 2015 Jan; 308(1):E84-95. PubMed ID: 25389364
[TBL] [Abstract][Full Text] [Related]
24. Preadipocyte 11beta-hydroxysteroid dehydrogenase type 1 is a keto-reductase and contributes to diet-induced visceral obesity in vivo.
De Sousa Peixoto RA; Turban S; Battle JH; Chapman KE; Seckl JR; Morton NM
Endocrinology; 2008 Apr; 149(4):1861-8. PubMed ID: 18174284
[TBL] [Abstract][Full Text] [Related]
25. 11Beta-hydroxysteroid dehydrogenase type 1 in human disease: a novel therapeutic target.
Tomlinson JW
Minerva Endocrinol; 2005 Mar; 30(1):37-46. PubMed ID: 15877012
[TBL] [Abstract][Full Text] [Related]
26. Minireview: 11beta-hydroxysteroid dehydrogenase type 1- a tissue-specific amplifier of glucocorticoid action.
Seckl JR; Walker BR
Endocrinology; 2001 Apr; 142(4):1371-6. PubMed ID: 11250914
[TBL] [Abstract][Full Text] [Related]
27. 11beta-hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action.
Draper N; Stewart PM
J Endocrinol; 2005 Aug; 186(2):251-71. PubMed ID: 16079253
[TBL] [Abstract][Full Text] [Related]
28. Tissue-specific dysregulation of cortisol metabolism in human obesity.
Rask E; Olsson T; Söderberg S; Andrew R; Livingstone DE; Johnson O; Walker BR
J Clin Endocrinol Metab; 2001 Mar; 86(3):1418-21. PubMed ID: 11238541
[TBL] [Abstract][Full Text] [Related]
29. Effect of hyperlipidemia on 11β-hydroxysteroid-dehydrogenase, glucocorticoid receptor, and leptin expression in insulin-sensitive tissues of cats.
Sieber-Ruckstuhl NS; Zini E; Osto M; Franchini M; Boretti FS; Meli ML; Sigrist B; Lutz TA; Reusch CE
Domest Anim Endocrinol; 2010 Nov; 39(4):222-30. PubMed ID: 20688460
[TBL] [Abstract][Full Text] [Related]
30. Growth hormone, insulin-like growth factor-I and the cortisol-cortisone shuttle.
Stewart PM; Toogood AA; Tomlinson JW
Horm Res; 2001; 56 Suppl 1():1-6. PubMed ID: 11786677
[TBL] [Abstract][Full Text] [Related]
31. Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11beta-hydroxysteroid dehydrogenase type 1 activity.
Rask E; Walker BR; Söderberg S; Livingstone DE; Eliasson M; Johnson O; Andrew R; Olsson T
J Clin Endocrinol Metab; 2002 Jul; 87(7):3330-6. PubMed ID: 12107245
[TBL] [Abstract][Full Text] [Related]
32. The functional consequences of 11beta-hydroxysteroid dehydrogenase expression in adipose tissue.
Tomlinson JW; Stewart PM
Horm Metab Res; 2002; 34(11-12):746-51. PubMed ID: 12660893
[TBL] [Abstract][Full Text] [Related]
33. Metabolic syndrome without obesity: Hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice.
Paterson JM; Morton NM; Fievet C; Kenyon CJ; Holmes MC; Staels B; Seckl JR; Mullins JJ
Proc Natl Acad Sci U S A; 2004 May; 101(18):7088-93. PubMed ID: 15118095
[TBL] [Abstract][Full Text] [Related]
34. Pharmacological evaluation of adipose dysfunction via 11β-hydroxysteroid dehydrogenase type 1 in the development of diabetes in diet-induced obese mice with cortisone pellet implantation.
Akiyama N; Akiyama Y; Kato H; Kuroda T; Ono T; Imagawa K; Asakura K; Shinosaki T; Murayama T; Hanasaki K
J Pharmacol Exp Ther; 2014 Apr; 349(1):66-74. PubMed ID: 24511146
[TBL] [Abstract][Full Text] [Related]
35. Genistein inhibits glucocorticoid amplification in adipose tissue by suppression of 11β-hydroxysteroid dehydrogenase type 1.
Tagawa N; Kubota S; Kobayashi Y; Kato I
Steroids; 2015 Jan; 93():77-86. PubMed ID: 25447798
[TBL] [Abstract][Full Text] [Related]
36. A polygenic model of the metabolic syndrome with reduced circulating and intra-adipose glucocorticoid action.
Morton NM; Densmore V; Wamil M; Ramage L; Nichol K; Bünger L; Seckl JR; Kenyon CJ
Diabetes; 2005 Dec; 54(12):3371-8. PubMed ID: 16306351
[TBL] [Abstract][Full Text] [Related]
37. Tissue-specific Cushing's syndrome, 11beta-hydroxysteroid dehydrogenases and the redefinition of corticosteroid hormone action.
Stewart PM
Eur J Endocrinol; 2003 Sep; 149(3):163-8. PubMed ID: 12943516
[TBL] [Abstract][Full Text] [Related]
38. 11beta-hydroxysteroid dehydrogenase type 1 as a novel therapeutic target in metabolic and neurodegenerative disease.
Walker BR; Seckl JR
Expert Opin Ther Targets; 2003 Dec; 7(6):771-83. PubMed ID: 14640912
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 in obesity.
Wake DJ; Walker BR
Endocrine; 2006 Feb; 29(1):101-8. PubMed ID: 16622297
[TBL] [Abstract][Full Text] [Related]
40. The role of 11beta-hydroxysteroid dehydrogenases in the brain.
Holmes MC; Seckl JR
Mol Cell Endocrinol; 2006 Mar; 248(1-2):9-14. PubMed ID: 16413106
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
